Histogen Inc., a clinical-stage therapeutics company, focuses on developing therapeutics based upon the products of fibroblast cells grown under simulated embryonic conditions. It offers HST-001, a hair stimulating complex that is in Phase 1b/2a clinical trial for the treatment of androgenic alopecia (hair loss); HST-003, a human extracellular matrix, which is in Phase 1/2 clinical trial to treat articular cartilage defects in the knee; and Emricasan, an orally active pan-caspase inhibitor that is in Phase 1 clinical trial for the treatment of COVID-19. The company's pre-clinical programs include HST-004, a cell conditioned media (CCM) solution to treat spinal disc repair; and HST-002, a human-derived collagen and extracellular matrix dermal filler for the treatment of facial folds and wrinkles. Histogen Inc. was founded in 2007 and is headquartered in San Diego, California.
IPO Year: 2013
Exchange: NASDAQ
Website: histogen.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/30/2021 | $2.40 | Buy | HC Wainwright & Co. |
SC 13G/A - Histogen Inc. (0001383701) (Subject)
SC 13G/A - Histogen Inc. (0001383701) (Subject)
SC 13G/A - Histogen Inc. (0001383701) (Subject)
SC 13G - Histogen Inc. (0001383701) (Subject)
15-12G - Histogen Inc. (0001383701) (Filer)
DEFA14A - Histogen Inc. (0001383701) (Filer)
425 - Histogen Inc. (0001383701) (Subject)
8-K - Histogen Inc. (0001383701) (Filer)
425 - Histogen Inc. (0001383701) (Subject)
8-K - Histogen Inc. (0001383701) (Filer)
S-8 POS - Histogen Inc. (0001383701) (Filer)
S-8 POS - Histogen Inc. (0001383701) (Filer)
S-8 POS - Histogen Inc. (0001383701) (Filer)
S-8 POS - Histogen Inc. (0001383701) (Filer)
SAN DIEGO, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:HSTO), a clinical-stage therapeutics company focused on developing its pan-caspase and caspase selective inhibitors as treatments for infectious and inflammatory diseases and has a pipeline of restorative therapeutics for orthopedic indications, today announced the appointment of Alfred P. Spada Ph.D. as Executive Vice President and Chief Scientific Officer. "We are very excited about Dr. Spada joining our management team. Dr. Spada is a world expert in both the biology of apoptosis and the chemistry of designing potent caspase inhibitors," said Steven J. Mento Ph.D., Executive Chairman and Interim President and Chief E
Pioneer in the field of regenerative medicine who brought four products from concept through FDA approval and market launch CEL-SCI Corporation (NYSE:CVM) today announced the appointment of Dr. Gail K. Naughton to its Board of Directors. Dr. Naughton has been a pioneer in the field of regenerative medicine for over 35 years. She was the founder of Advanced Tissue Sciences (NASDAQ:ATIS) where she oversaw the design and development of the world's first up-scaled manufacturing facility for cell-based products, established corporate development and marketing partnerships with companies including Smith & Nephew, Medtronic, and Inamed Corporation, was pivotal in raising over $350 million from t
A proven industry leader and executive, Ryan Fernan, will help ORHub advance Ortho-Spine technology beyond current limitations.IRVINE, CA / ACCESSWIRE / July 27, 2022 / ORHub, Inc. (OTC:ORHB) officially kicks off the acquisition of PUR Biologics ("PUR") with the appointment of Ryan Fernan as the Head of PUR Biologics. An ORHub biotech company, PUR Biologics is focused on delivering next generation regenerative biologic products to address degenerative musculoskeletal diseases.Mr. Fernan, brings direct access to a broad industry network with a proven track record of over 18 years in the medical device and biotechnology industry. Recognized as a frontrunner in sales and product development, Mr
Paracrine, Inc., a company developing its novel cell therapy platform in late-stage clinical trials in advanced wound care, announced today the appointment of David Crean, Ph.D. as an independent Director of the company. "We are delighted to welcome David Crean to the Paracrine Board," said Christopher J. Calhoun, Chairman and CEO of Paracrine. "David's deep experience in the healthcare and biotechnology fields will provide immense value to Paracrine as we continue to execute our strategy of developing safe, cost-effective cell therapies in the $21 billion wound care market." "I am happy to join Paracrine's Board of Directors at this exciting time in the company's development," added Davi
SAN DIEGO, March 10, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases, today reported financial results for the fourth quarter and year ended December 31, 2021 and provided an update on its clinical pipeline and other corporate developments. "We have a diverse pipeline of biologics and small molecule product candidates that we believe address large unmet market needs," said Steven J. Mento, Ph.D., Interim President and Chief Executive Officer. "Looking ahead, we will continue to fo
SAN DIEGO, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain healthy biological function, today announced that that Steven J. Mento, Ph.D., a current member of the Histogen Board of Directors, has been appointed Executive Chairman and Interim President and Chief Executive Officer effective immediately. David Crean, Ph.D., a current member and the Chairman of the Histogen Board of Directors, will continue to serve as a member of the Board of Directors and as the newly appointed Lead Independent Director. Rich
SAN DIEGO, March 25, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function has appointed Rochelle Fuhrmann to its Board of Directors and Chairperson of the Audit Committee. In addition, current director Stephen Chang, Ph.D. will be resigning from the Board. “I am honored and excited to join the Histogen board during this transformational period and I look forward to working with the board and management to build upon the work that has been done to create value for all company stakeholders,”
Meeting Adjourned for a Final Time to January 4, 2024 at 8:00 a.m. PTPotential Estimated Cash Distribution to Shareholders of $0.30 to $0.41 if Dissolution Proposal Approved SAN DIEGO, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (OTC:HSTO), today announced that its special meeting of stockholders (the "Special Meeting") has been adjourned to Thursday, January 4, 2024 at 8:00 a.m. Pacific Time with respect to both proposals described in its definitive proxy statement filed with the U.S. Securities and Exchange Commission (the "SEC") on October 18, 2023 (the "Proxy Statement"). The Special Meeting, which will be reconvened for a final time on January 4, 2024, will continue to be held v
SAN DIEGO, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (OTC:HSTO) today announced that its special meeting of stockholders (the "Special Meeting") has been adjourned to Thursday, December 14, 2023 at 8:00 a.m. Pacific Time with respect to both proposals described in its definitive proxy statement filed with the U.S. Securities and Exchange Commission (the "SEC") on October 18, 2023 (the "Proxy Statement"). The reconvened Special Meeting on December 14, 2023 will continue to be held via live webcast at www.virtualshareholdermeeting.com/HSTO2023SM. In addition, the record date for determining stockholders entitled to vote at the Special Meeting will remain the close of business on Octob
SAN DIEGO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:HSTO), today announced that its Board of Directors, after extensive consideration of potential strategic alternatives, has approved and adopted a Plan of Dissolution ("Plan of Dissolution") that would include the distribution of remaining cash to stockholders following an orderly wind down of the company's operations, including any proceeds from the potential sale of any pipeline assets. In order to reduce costs and in connection with the Plan of Dissolution, the company has discontinued all clinical development programs and reduced its workforce, including the anticipated termination of most employees by the end of Septem
SAN DIEGO, July 05, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body's natural process to restore immune function, today announced that it has completed a review of its business, including the status of programs, resources and capabilities, and has decided to pause further development of its programs and commence a process to explore strategic alternatives with the intent to enhance shareholder value. Histogen has engaged Roth Capital Partners, LLC, to act as a strategic advisor in this process.
Received FDA Clearance of IND Application for Emricasan for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Emricasan Treatment has Therapeutic Effect Against Bacterial Skin Infection in Mice Signed Exclusive Intellectual Property License Agreement with Johns Hopkins University Steven J. Mento Ph.D. Appointed President and CEO SAN DIEGO, May 11, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body's natural process to restore immune function, today rep
Emricasan Treatment has Therapeutic Effect Against Bacterial Skin Infection in Mice Pipeline Focus on Pan-Caspase and Caspase Selective Inhibitors for Infectious and Inflammatory Diseases SAN DIEGO, April 20, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body's natural process to restore immune function, today announced the online publication of an abstract describing a preclinical study showing that emricasan has therapeutic effect against bacterial skin infections. In the study, the role
Licensed Patents Expected to Provide Freedom to Operate and Exclusivity for Emricasan Pipeline Focus on Pan-Caspase and Caspase Selective Inhibitors for Infectious and Inflammatory Diseases SAN DIEGO, April 03, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body's natural process to restore immune function, today announced that the company has signed an exclusive license agreement with Johns Hopkins University. The intellectual property associated with this license covers the use of emricasan for
The Newly Issued Patent is Expected to Provide Protection into 2040 Pipeline Focus on Pan-Caspase and Caspase Selective Inhibitors for Infectious and Inflammatory Diseases SAN DIEGO, March 16, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:HSTO), a clinical-stage therapeutics company on developing potential first-in-class clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body's natural process to restore immune function, today announced that the US Patent and Trademark Office (USPTO) has issued US Patent No. 11,579,703 titled "Caspase Inhibitors and Methods of Use Thereof." We believe this key patent provides broad coverage for Histo
SAN DIEGO, March 09, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:HSTO), a clinical-stage therapeutics company on developing potential first-in-class clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body's natural process to restore immune function, today reported financial results for the year ended December 31, 2022, and provided an update on its pipeline and other corporate developments. "Our team is very excited about the new direction of the company. We remain focused on the development of emricasan as a potential treatment for acute bacterial skin and skin structure infections (ABSSSI), including those related to methicillin res
SAN DIEGO, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:HSTO), a clinical-stage therapeutics company focused on developing its pan-caspase and caspase selective inhibitors as treatments for infectious and inflammatory diseases and has a pipeline of restorative therapeutics for orthopedic indications, today announced the Board of Directors, upon the recommendation of the Company's Compensation Committee granted Alfred J. Spada, the company's recently appointed Executive Vice President and Chief Scientific Officer, a nonqualified stock option to purchase 106,793 shares of Histogen Inc. common stock with an exercise price of $1.04 based on the closing price on February 23, 2023, th
HC Wainwright & Co. initiated coverage of Histogen with a rating of Buy and set a new price target of $2.40
Canaccord Genuity reiterated coverage of Histogen with a rating of Buy and set a new price target of $4.00 from $5.00 previously
Canaccord Genuity initiated coverage of Histogen with a rating of Buy and set a new price target of $5.00
Canaccord Genuity initiated coverage of Histogen with a rating of Buy and set a new price target of $5.00
Canaccord Genuity initiated coverage of Histogen with a rating of Buy
4 - Histogen Inc. (0001383701) (Issuer)
4 - Histogen Inc. (0001383701) (Issuer)
4 - Histogen Inc. (0001383701) (Issuer)
4 - Histogen Inc. (0001383701) (Issuer)
4 - Histogen Inc. (0001383701) (Issuer)
4 - Histogen Inc. (0001383701) (Issuer)
4/A - Histogen Inc. (0001383701) (Issuer)
4 - Histogen Inc. (0001383701) (Issuer)
4 - Histogen Inc. (0001383701) (Issuer)
4 - Histogen Inc. (0001383701) (Issuer)
SAN DIEGO, March 09, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:HSTO), a clinical-stage therapeutics company on developing potential first-in-class clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body's natural process to restore immune function, today reported financial results for the year ended December 31, 2022, and provided an update on its pipeline and other corporate developments. "Our team is very excited about the new direction of the company. We remain focused on the development of emricasan as a potential treatment for acute bacterial skin and skin structure infections (ABSSSI), including those related to methicillin res
SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics for orthopedic indications and pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases, today reported financial results for the third quarter ended September 30, 2022 and provided an update on its clinical pipeline and other corporate developments. "We remain focused on the feasibility of developing emricasan as a potential treatment for bacterial skin infections including those related to methicillin resistant staphylococcus aureus ("MRSA") and evaluating our caspase-1 inh
Closed $5M Financing in July Regained Compliance with Nasdaq Minimum Bid Price Requirement SAN DIEGO, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics for orthopedic indications and pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases, today reported financial results for the second quarter ended June 30, 2022 and provided an update on its clinical pipeline and other corporate developments. "We continue to focus on execution of IND enabling activities for HST 004 in spinal disc regeneration, exploration of testing emricasan in ani
SAN DIEGO, July 27, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases, today announced that Histogen's financial results for the second quarter ended June 30, 2022 will be released after the close of market on Thursday, August 11, 2022. About Histogen Inc. Histogen Inc. is a clinical-stage therapeutics company focused on developing both potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain healthy biological function as well
SAN DIEGO, April 28, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases, today announced that Histogen's financial results for the first quarter ended March 31, 2022 will be released after the close of market on Thursday, May 12, 2022. About Histogen Inc. Histogen Inc. is a clinical-stage therapeutics company focused on developing both potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain healthy biological function as well as a
SAN DIEGO, March 03, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain healthy biological function, today announced that Histogen's financial results for the fourth quarter and year ended December 31, 2021 will be released after the close of market on Thursday, March 10, 2022. About Histogen Inc. Histogen Inc. is a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain healthy biological function. Hist
SAN DIEGO, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain healthy biological function, today announced that Histogen's financial results for the third quarter will be released after the close of market on Wednesday, November 10, 2021. About Histogen Inc. Histogen Inc. is a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain healthy biological function. Histogen's innovative technology pl
SAN DIEGO, July 28, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain healthy biological function, today announced that Histogen's financial results for the second quarter will be released after the close of market on Wednesday, August 11, 2021. About Histogen Inc. Histogen Inc. is a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain healthy biological function. Histogen's innovative technology pla